display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced RCC (mRCC) - 1st line (L1)
metastatic/advanced RCC (mRCC) - 1st line (L1)
nivolumab based treatment
nivolumab plus cabozantinib CheckMate 9ER

Study type: